Sunshine Biopharma appoints Michel Roy as Chief Commercial Officer

Sunshine Biopharma Inc.

Michel Roy appointed CCO effective Jan 13, 2025; initial base salary of $400,000 CAD annually.
Severance of $500,000 CAD payable if terminated without cause, plus minimum statutory notice.
Roy previously led Canadian ops of Shilpa Medicare (2020-2024) and was VP at Intas Pharmaceuticals (2014-2020).
Responsibilities include overseeing commercial strategy, sales, marketing, and business development.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michel Roy

Chief Commercial Officer

SBFM · Sunshine Biopharma Inc.

Effective: 2025-01-13
Filed: January 15, 2025, 6:59 PM ET

On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michel Roy was appointed as Chief Commercial Officer at Sunshine Biopharma Inc..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.

View on SEC.gov

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-25-000357

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.